Atlas Venture Life Science Advisors, LLC Dyne Therapeutics, Inc. Transaction History
Atlas Venture Life Science Advisors, LLC
- $443 Million
- Q3 2025
A detailed history of Atlas Venture Life Science Advisors, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Atlas Venture Life Science Advisors, LLC holds 9,130,465 shares of DYN stock, worth $172 Million. This represents 26.07% of its overall portfolio holdings.
Number of Shares
9,130,465
Previous 9,130,465
-0.0%
Holding current value
$172 Million
Previous $86.9 Million
32.88%
% of portfolio
26.07%
Previous 19.12%
Shares
6 transactions
Others Institutions Holding DYN
# of Institutions
227Shares Held
148MCall Options Held
184KPut Options Held
243K-
Janus Henderson Group PLC London, X014.7MShares$278 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.76MShares$184 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$139 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$103 Million13.81% of portfolio
-
State Street Corp Boston, MA5.27MShares$99.3 Million0.0% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $975M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...